Coverage
-
June 28, 2013
A New Jersey pain medicine manufacturer that was temporarily shut down after authorities discovered mold in its injectable drug products agreed Thursday to cease operations until it fulfills a raft of compliance obligations mandated by the U.S. Food and Drug Administration.
1 other articles on this case.
View all »